

ACI Formulations Limited

1st Quarter Report 2019-2020

ACI Formulations Limited

Statement of financial position
Unaudited

Figures in "000"

<i>In Taka</i>	Note	As at 30 September 2019	As at 30 June 2019 * Restated	As at 1 July 2018 * Restated
Assets				
Property, plant and equipment	5	1,928,562	1,944,656	1,793,503
Right-of-use assets		19,058	21,371	11,784
Investments	6	39,742	39,742	37,096
Non-current assets		1,987,362	2,005,769	1,842,383
Inventories	8	1,510,775	1,625,583	1,610,649
Trade receivables	9	1,690,595	1,713,472	1,350,155
Other receivables		47,749	41,729	27,351
Inter-company receivables	10	21,484	22,983	516,616
Advances, deposits and prepayments	11	675,990	646,690	498,330
Cash and cash equivalents		140,943	297,708	262,040
Current assets		4,087,536	4,348,165	4,265,141
Total assets		6,074,898	6,353,934	6,107,524
Equity				
Share capital		450,000	450,000	450,000
Revaluation reserve		1,136,393	1,136,393	1,136,393
Retained earnings		891,933	885,396	915,381
Total equity		2,478,326	2,471,789	2,501,774
Liabilities				
Employee benefits	12	46,081	43,495	39,179
Deferred tax liabilities		46,129	48,918	59,325
Lease liabilities		13,760	16,111	10,525
Non-current liabilities		105,970	108,524	109,029
Bank overdrafts		149,768	128,759	163,498
Loans and borrowings		1,888,068	1,822,161	2,738,696
Lease liabilities- current portion		7,473	7,257	2,005
Trade payables		77,628	89,051	126,995
Other payables	13	177,663	248,013	196,584
Inter-company payables	14	851,740	1,146,287	-
Provision for tax		338,263	332,093	268,943
Current liabilities		3,490,603	3,773,621	3,496,721
Total liabilities		3,596,572	3,882,145	3,605,750
Total equity and liabilities		6,074,898	6,353,934	6,107,524
Net asset value (NAV) per share		55.07	54.93	55.59


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited

Statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

For the 1st quarter ended from

<i>In Taka</i>	Note	July 2019	July 2018
		to September 2019	to September 2018
			Restated*
Revenue	15	750,069	939,136
Cost of sales	16	(500,038)	(661,491)
Gross profit		250,031	277,645
Other income		1,884	1,100
Administrative, selling and distribution expenses	17	(179,363)	(205,295)
Operating profit		72,552	73,450
Finance costs, net		(62,112)	(48,178)
Profit before contribution to WPPF		10,440	25,272
Contribution to WPPF		(522)	(1,287)
Profit before tax		9,918	23,985
Tax expenses		(3,381)	(6,983)
Profit after tax		6,537	17,002
Other comprehensive income		-	-
Total comprehensive income		6,537	17,002
Earnings per share			
Basic earnings per share (BEPS)		0.15	0.38


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited
Statement of changes in equity
Unaudited

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2019			
	Attributable to owner of the Company			
	Share capital	Revaluation reserve	Retained earnings	Total
Balance at 1 July 2019 as previously reported	450,000	1,136,393	886,894	2,473,287
Impact of initial application of IFRS 16	-	-	(1,498)	(1,498)
Restated balance at 1 July 2019	450,000	1,136,393	885,396	2,471,789
Total comprehensive income				
Profit for the period	-	-	6,537	6,537
Total comprehensive income	-	-	6,537	6,537
Transactions with owners of the company				
Contributions and distributions	-	-	-	-
Issue of bonus shares	-	-	-	-
Dividends	-	-	-	-
Total transactions with owners of the company	-	-	-	-
Balance at 30 September 2019	450,000	1,136,393	891,933	2,478,326

<i>In Taka</i>	For the 1st quarter ended 30 September 2018			
	Attributable to owner of the Company			
	Share capital	Revaluation reserve	Retained earnings	Total
Balance at 1 July 2018, as previously reported	450,000	1,136,393	915,940	2,502,333
Impact of initial application of IFRS 16	-	-	(559)	(559)
Restated balance at 1 July 2018	450,000	1,136,393	915,381	2,501,774
Total comprehensive income				
Profit for the period	-	-	17,002	17,002
Total comprehensive income	-	-	17,002	17,002
Transactions with owners of the company				
Contributions and distributions	-	-	-	-
Issue of bonus shares	-	-	-	-
Dividends	-	-	-	-
Total transactions with owners of the company	-	-	-	-
Balance at 30 September 2018	450,000	1,136,393	932,383	2,518,776

ACI Formulations Limited

Statement of cash flows
Unaudited

<i>In Taka</i>	Note	Figures in "000"	
		For the 1st quarter ended from	
		July 2019 to September 2019	July 2018 to September 2018 Restated*
Cash flows from operating activities			
Cash received from customers and others		773,629	789,239
Cash paid to suppliers and employees		(642,870)	(870,520)
Cash (used in)/generated from operating activities		130,759	(81,281)
Interest paid		(63,929)	(79,118)
Income tax paid		(14,821)	(29,633)
		(78,750)	(108,751)
Net cash (used in)/generated from operating activities*	18	52,009	(190,032)
Cash flows from investing activities			
Acquisition of property, plant and equipment		(689)	(52,584)
Net cash (used in)/generated from investing activities		(689)	(52,584)
Cash flows from financing activities			
Inter-company debts received/(paid)		(293,048)	1,286,975
Proceeds from loans and borrowings		65,907	(1,118,972)
Payment for lease liability		(1,953)	(1,138)
Net cash (used in)/generated from financing activities		(229,094)	166,865
Net increase in cash and cash equivalents		(177,774)	(75,751)
Cash and cash equivalents as at 1 July		168,949	98,542
Cash and cash equivalents as at 30 September		(8,825)	22,791
Closing balance represents			
Cash and cash equivalents		140,943	135,578
Bank overdraft		(149,768)	(112,787)
		(8,825)	22,791
Net operating cash flow per share (NOCFPS)		1.16	(4.22)


* See Note 18 for reconciliation of net operating cash flow.

ACI Formulations Limited
Consolidated Statement of Financial Position
Unaudited


Figures in "000'

<i>In Taka</i>	Note	As at 30 September 2019	As at 30 June 2019 * Restated	As at 1 July 2018 * Restated
Assets				
Property, plant and equipment	5(a)	1,930,218	1,946,404	1,795,746
Right-of-use assets		19,058	21,371	11,784
Investments	6(a)	35,794	35,794	33,148
Intangible assets	7	5,148	5,148	5,148
Non-current assets		1,990,218	2,008,717	1,845,826
Inventories	8(a)	1,510,781	1,641,861	1,629,234
Trade receivables	9(a)	1,691,659	1,718,347	1,360,567
Other receivables		46,132	41,674	26,004
Inter-company receivable	10(a)	20,660	3,658	490,418
Advances, deposits and prepayments	11(a)	679,954	649,979	500,830
Cash and cash equivalents		140,210	298,654	262,105
Current assets		4,089,396	4,354,173	4,269,158
Total assets		6,079,614	6,362,890	6,114,984
Equity				
Share capital		450,000	450,000	450,000
Revaluation reserve		1,136,393	1,136,393	1,136,393
Retained earnings		886,991	880,352	908,470
Equity attributable to the owner of the Company		2,473,384	2,466,745	2,494,863
Non controlling interest		(125)	(127)	(165)
Total equity		2,473,259	2,466,618	2,494,698
Liabilities				
Employee benefits	12	46,081	43,495	39,179
Deferred tax liabilities		45,832	48,621	58,341
Lease liabilities		13,760	16,111	10,525
Non-current liabilities		105,673	108,227	108,045
Bank overdrafts		149,768	128,759	163,497
Loans and borrowings		1,891,406	1,825,022	2,746,379
Lease liabilities- current portion		7,473	7,257	2,005
Trade payables		80,944	97,424	132,431
Other payables	13(a)	179,499	249,644	197,589
Inter-company payables	14	851,740	1,146,287	-
Provision for tax		339,852	333,652	270,340
Current liabilities		3,500,682	3,788,045	3,512,241
Total liabilities		3,606,355	3,896,272	3,620,286
Total equity and liabilities		6,079,614	6,362,890	6,114,984
Net asset value (NAV) per share		54.96	54.82	55.44


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited

Consolidated statement of profit or loss and other comprehensive income
Unaudited

<i>In Taka</i>	Note	Figures in "000"	
		For the 1st quarter ended from July 2019 to September 2019	July 2018 to September 2018
			Restated*
Revenue	15(a)	750,363	949,013
Cost of sales	16(a)	(500,038)	(670,021)
Gross profit		250,325	278,992
Other income		1,884	1,100
Administrative, selling and distribution expenses	17(a)	(179,524)	(205,464)
Operating profit		72,685	74,628
Finance costs, net		(62,112)	(48,295)
Profit before contribution to WPPF		10,573	26,333
Contribution to WPPF		(522)	(1,287)
Profit before tax		10,051	25,046
Income tax expenses		(3,410)	(7,463)
Profit after tax		6,641	17,583
Other comprehensive income		-	-
Total comprehensive income		6,641	17,583
Total comprehensive income attributable to:			
Owners of the Company		6,639	17,571
Non controlling interest		2	12
		6,641	17,583
Earnings per share			
Basic earnings per share (BEPS)		0.15	0.39


Managing Director


Director


Chief Financial Officer


Company Secretary

ACI Formulations Limited

Consolidated statement of changes in equity
Unaudited

Figures in "000"

<i>In Taka</i>	For the 1st quarter ended 30 September 2019					
	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2019 as previously reported	450,000	1,136,393	881,850	2,468,243	(127)	2,468,116
Impact of initial application of IFRS 16	-	-	(1,498)	(1,498)	-	(1,498)
Restated balance at 1 July 2019	450,000	1,136,393	880,352	2,466,745	(127)	2,466,618
Total comprehensive income						
Profit for the period	-	-	6,639	6,639	2	6,641
Total comprehensive income	-	-	6,639	6,639	2	6,641
Transactions with owners of the company						
Contributions and distributions						
Dividends paid	-	-	-	-	-	-
Total transactions with owners of the company	-	-	-	-	-	-
Balance as at 30 September 2019	450,000	1,136,393	886,991	2,473,384	(125)	2,473,259

<i>In Taka</i>	For the 1st quarter ended 30 September 2018					
	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2018, as previously reported	450,000	1,136,393	909,029	2,495,422	(165)	2,495,257
Impact of initial application of IFRS 16	-	-	(559)	(559)	-	(559)
Restated balance at 1 July 2018	450,000	1,136,393	908,470	2,494,863	(165)	2,494,698
Total comprehensive income						
Profit for the period	-	-	17,571	17,571	12	17,583
Total comprehensive income	-	-	17,571	17,571	12	17,583
Transactions with owners of the company						
Contributions and distributions						
Dividends paid	-	-	-	-	-	-
Total transactions with owners of the company	-	-	-	-	-	-
Balance as at 30 September 2018	450,000	1,136,393	926,041	2,512,434	(153)	2,512,281

ACI Formulations Limited
 Consolidated statement of cash flows
 Unaudited

Figures in "000".

<i>In Taka</i>	Note	For the 1st quarter ended from	
		July 2019 to September 2019	July 2018 to September 2018
			Restated*
Cash flows from operating activities			
Cash received from customers and others		777,734	787,712
Cash paid to suppliers and employees		(647,224)	(867,464)
Cash (used in)/generated from operating activities		130,510	(79,752)
Interest paid		(63,929)	(79,235)
Income tax paid		(14,888)	(29,633)
		(78,817)	(108,868)
Net cash (used in)/generated from operating activities*	18 (a)	51,693	(188,620)
Cash flows from investing activities			
Acquisition of property, plant and equipment		(689)	(52,584)
Net cash (used in)/generated from investing activities		(689)	(52,584)
Cash flows from financing activities			
Inter-company debts received/(paid)		(294,890)	1,286,975
Proceeds from loans and borrowings		66,385	(1,122,364)
Payment for lease liability		(1,953)	(1,138)
Net cash (used in)/generated from financing activities		(230,458)	163,473
Net increase in cash and cash equivalents		(179,454)	(77,731)
Cash and cash equivalents as at 1 July		169,896	98,608
Cash and cash equivalents as at 30 September		(9,558)	20,877
Closing balance represents			
Cash and cash equivalents		140,210	133,664
Bank overdraft		(149,768)	(112,787)
		(9,558)	20,877
Net operating cash flow per share (NOCFPS)		1.15	(4.19)

* See Note 18(a) for reconciliation of consolidated net operating cash flow.

ACI Formulations Limited

**Notes to the financial statements
as at and for the 1st quarter ended on 30 September 2019
Unaudited**

1. Company profile:

ACI Formulations Limited, a subsidiary of Advanced Chemical Industries Limited, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

2. Subsidiaries of ACI Formulations Limited:

ACI Formulations Limited has one subsidiary namely Neem Laboratories (Pvt.) Ltd, engaged in manufacturing and marketing of herbal products . ACI Formulations Limited through its voting rights controls the operating and financing activities of this entity.

3. Consolidated Financial statements:

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per BFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per BAS 27: Separate Financial Statements.

4. Selected explanatory notes:

These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2019. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

	Figures in '000'	
	<u>30- Sep -19</u>	<u>30-June -19</u>
	<u>Taka</u>	<u>Taka</u>
5 Property, plant & equipment		
Opening balance	2,156,021	1,937,597
Addition during the period/year	563	218,424
	<u>2,156,584</u>	<u>2,156,021</u>
Accumulated depreciation at the end of period/year	<u>(228,022)</u>	<u>(211,365)</u>
Closing balance	<u>1,928,562</u>	<u>1,944,656</u>

	<u>30- Sep -19</u> <u>Taka</u>	<u>30-June -19</u> <u>Taka</u>
5(a) Property, plant & equipment		
Opening balance	2,160,982	1,942,558
Addition during the period/year	563	218,424
	<u>2,161,545</u>	<u>2,160,982</u>
Accumulated depreciation at the end of period/year	(231,327)	(214,578)
Closing balance	<u><u>1,930,218</u></u>	<u><u>1,946,404</u></u>
6. Investments		
Investment in susidiary	3,948	3,948
Investment in FDR	35,719	35,719
Investment in shares of ACI Motors Limited	75	75
	<u>39,742</u>	<u>39,742</u>
6(a) Consolidated investments		
Investment in FDR	35,719	35,719
Investment in Shares- ACI Motors Limited	75	75
	<u>35,794</u>	<u>35,794</u>
7. Intangible assets		
Goodwill on acquisition :		
Neem Laboratories (Pvt.) Limited	5,148	5,148
	<u>5,148</u>	<u>5,148</u>
8. Inventories		
Raw and packing materials	701,991	823,197
Finished goods	701,987	724,125
Goods in transit	97,315	66,926
Other inventories	25,896	25,972
Allowances for slow moving inventory	(16,414)	(14,637)
	<u>1,510,775</u>	<u>1,625,583</u>
8(a). Consolidated inventories		
Raw and packing materials	701,991	837,461
Finished goods	702,263	726,307
Stock in transit	97,322	67,705
Other inventories	25,896	25,972
Allowances for slow moving inventory	(16,691)	(15,584)
	<u>1,510,781</u>	<u>1,641,861</u>
9. Trade receivables:		
Related parties	-	-
Other than related parties	1,834,028	1,856,389
	<u>1,834,028</u>	<u>1,856,389</u>
Allowances for doubtful debts	(143,433)	(142,917)
	<u>1,690,595</u>	<u>1,713,472</u>
Below six months	1,408,020	1,401,909
Over six months	426,008	454,480
Allowances for doubtful debts	(143,433)	(142,917)
	<u>1,690,595</u>	<u>1,713,472</u>

	<u>30- Sep -19</u> <u>Taka</u>	<u>30-June -19</u> <u>Taka</u>
9(a). Consolidated trade receivables		
Related parties	-	-
Other than related parties	<u>1,835,093</u>	<u>1,861,264</u>
	<u>1,835,093</u>	<u>1,861,264</u>
Allowances for doubtful debts	<u>(143,433)</u>	<u>(142,917)</u>
	<u><u>1,691,660</u></u>	<u><u>1,718,347</u></u>
Below six months	<u>1,409,084</u>	<u>1,406,784</u>
Over six months	<u>426,008</u>	<u>454,480</u>
Allowances for doubtful debts	<u>(143,433)</u>	<u>(142,917)</u>
	<u><u>1,691,659</u></u>	<u><u>1,718,347</u></u>
10 . Inter-company receivables		
Neem Laboratories (Pvt.) Ltd.	<u>21,484</u>	<u>22,983</u>
	<u><u>21,484</u></u>	<u><u>22,983</u></u>
10(a) . Consolidated inter-company receivables		
ACI Limited	<u>20,660</u>	<u>3,658</u>
	<u><u>20,660</u></u>	<u><u>3,658</u></u>
11. Advances, deposits & prepayments		
Advances:		
Staffs	<u>371</u>	<u>591</u>
Suppliers & others	<u>58,273</u>	<u>40,985</u>
VAT current account	<u>529</u>	<u>9,542</u>
Advance income tax (Note- 11.1)	<u>575,683</u>	<u>560,862</u>
	<u><u>634,856</u></u>	<u><u>611,980</u></u>
Deposits:		
Security deposits	<u>14,092</u>	<u>11,704</u>
Bank guarantee margin	<u>18,093</u>	<u>18,093</u>
	<u><u>32,185</u></u>	<u><u>29,797</u></u>
Prepayments:		
Prepaid expenses	<u>8,949</u>	<u>4,913</u>
	<u><u>8,949</u></u>	<u><u>4,913</u></u>
	<u><u>675,990</u></u>	<u><u>646,690</u></u>
11.1 Advance income tax		
Opening balance	<u>560,862</u>	<u>403,492</u>
Paid during the period/year	<u>14,821</u>	<u>157,370</u>
Closing balance	<u><u>575,683</u></u>	<u><u>560,862</u></u>

	<u>30- Sep -19</u>	<u>30-June -19</u>
	<u>Taka</u>	<u>Taka</u>
11(a). Consolidated advances, deposits & prepayments		
Advances:		
Staff	371	591
Suppliers & others	59,002	41,893
VAT current account	2,182	10,408
Advance income tax	577,265	562,377
	<u>638,820</u>	<u>615,269</u>
Deposits:		
Security deposits	14,092	11,704
Bank guarantee margin	18,093	18,093
	<u>32,185</u>	<u>29,797</u>
Prepayments:		
Prepaid expenses	8,949	4,913
	<u>8,949</u>	<u>4,913</u>
	<u>679,954</u>	<u>649,979</u>
12. Employee benefits		
Defined benefit obligation	34,981	32,395
Other employee benefits	11,100	11,100
	<u>46,081</u>	<u>43,495</u>
13. Other payables		
Creditor for expenses	134,561	193,889
Interest payable	13,965	16,289
Security money payable	11,566	11,766
Unpaid dividend	11,810	11,810
Withholding tax and VAT	5,239	4,706
Provision for workers' profit participation fund	522	9,553
	<u>177,663</u>	<u>248,013</u>
13(a). Consolidated other payables		
Creditor for expenses	136,202	195,339
Interest payable	13,965	16,289
Security money payable	11,566	11,766
Unpaid dividend	11,810	11,810
Withholding tax and VAT	5,434	4,887
Provision for workers' profit participation fund	522	9,553
	<u>179,499</u>	<u>249,644</u>
14. Inter-company payables		
ACI Limited	851,740	1,146,287
	<u>851,740</u>	<u>1,146,287</u>

		<u>1st quarter ended on</u>	
		<u>30-Sep-19</u>	<u>30-Sep-18</u>
		<u>Taka</u>	<u>Taka</u>
15.	Revenue		
	Crop Care & Public Health	539,736	607,835
	Mosquito Coil	4,494	32,027
	Aerosol	82,811	145,244
	Paint	118,922	141,498
	Vanish	4,106	12,532
		<u>750,069</u>	<u>939,136</u>
15(a).	Consolidated revenue		
	Crop Care & Public Health	539,736	607,835
	Mosquito Coil	4,494	32,027
	Aerosol	82,811	145,244
	Paint	118,922	141,498
	Others	4,400	22,409
		<u>750,363</u>	<u>949,013</u>
16.	Cost of sales		
	Opening stock	1,547,323	1,468,094
	Purchase	307,991	665,522
		<u>1,855,314</u>	<u>2,133,616</u>
	Closing stock	(1,403,978)	(1,530,694)
		451,336	602,922
	Manufacturing expenses	48,702	58,569
		<u>500,038</u>	<u>661,491</u>
16(a).	Consolidated cost of sales		
	Opening stock	1,563,768	1,482,299
	Purchase	307,991	676,833
		<u>1,871,759</u>	<u>2,159,132</u>
	Stock transferred to ACI Limited	(15,498)	-
	Closing stock	(1,404,254)	(1,547,910)
		452,007	611,222
	Manufacturing expenses	48,031	58,799
		<u>500,038</u>	<u>670,021</u>
17.	Administrative, selling and distribution expenses		
	Administrative expenses	23,195	27,627
	Distribution expenses	28,083	25,022
	Selling expenses	128,085	152,646
		<u>179,363</u>	<u>205,295</u>
17(a).	Consolidated administrative, selling and distribution expenses		
	Administrative expenses	23,356	27,796
	Distribution expenses	28,083	25,022
	Selling expenses	128,085	152,646
		<u>179,524</u>	<u>205,464</u>

18. **Reconciliation of net operating cash flow**

<i>In Taka</i>	1st quarter ended on	
	30-Sep-19	30-Sep-18
Profit after tax	6,662	17,358
Adjustment for non cash items and others:		
- Depreciation and amortization	16,788	17,196
- Provisions	2,977	20,807
- Net finance cost	(2,155)	(31,441)
- Tax expense	(11,396)	(22,531)
- Contribution to WPPF	(9,022)	1,287
Changes in:		
- Inventories	113,032	(6,854)
- Trade and other receivables	15,656	(150,956)
- Advances, deposit and prepayments	(12,526)	(17,578)
- Trade and other payables, employment benefits'	(68,007)	(17,320)
Cash generating from operating activities	52,009	(190,032)

18 (a). **Reconciliation of consolidated net operating cash flow**

<i>In Taka</i>	1st quarter ended on	
	30-Sep-19	30-Sep-18
Profit after tax	6,765	17,939
Adjustment for:		
- Depreciation and amortization	16,881	17,352
- Bad debts and inventory loss/(recovery)	2,307	20,807
- Net finance cost	(2,323)	(31,441)
- Tax expense	(11,433)	(22,051)
- Contribution to WPPF	(9,022)	1,287
Changes in:		
- Inventories	114,875	(6,905)
- Trade and other receivables	21,768	(162,136)
- Advances, deposit and prepayments	(13,134)	(17,991)
- Trade and other payables, employment benefits'	(74,991)	(5,481)
Cash generating from operating activities	51,693	(188,620)

19. Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

Crop Care and Public Health (CC & PH) To manufacture and sell crop care and public health products.

Mosquito Coil (M. Coil) To manufacture and sell mosquito coil products

Aerosol To manufacture and sell aerosol and air freshener products.

Paint To manufacture and sell of paint products.

Figures in '000'

Particulars	CC & PH		M. Coil		Aerosol		Paint		Unallocated		Total	
	1st Quarter ended on		1st Quarter ended on		1st Quarter ended on		1st Quarter ended on		1st Quarter ended on		1st Quarter ended on	
	Taka	30-Sep-18	Taka	30-Sep-18	Taka	30-Sep-18	Taka	30-Sep-18	Taka	30-Sep-18	Taka	30-Sep-18
Segment revenue:												
External revenues	539,736	607,835	4,494	32,027	82,811	145,244	118,922	141,498	4,106	12,532	750,069	939,136
Inter-segment revenues	-	-	-	-	-	-	-	-	294	9,877	294	9,877
Total revenue	539,736	607,835	4,494	32,027	82,811	145,244	118,922	141,498	4,400	22,409	750,363	949,013
Financing costs	(50,610)	(40,665)	-	-	-	-	(10,996)	(7,012)	(506)	(618)	(62,112)	(48,295)
Depreciation	(8,363)	(8,361)	(141)	(6,016)	(1,521)	(1,549)	(1,149)	(1,047)	(318)	(378)	(11,492)	(17,351)
Cost of sales excluding depreciation	(332,500)	(373,259)	(3,874)	(23,759)	(64,891)	(129,885)	(88,798)	(109,603)	(2,821)	(19,593)	(492,884)	(656,099)
Operating expenses excluding depreciation	(135,048)	(167,900)	(1,983)	(998)	(1,945)	(1,217)	(35,487)	(30,828)	(724)	(1,095)	(175,187)	(202,038)
Other income/(expense)	1,560	707	-	-	52	230	273	163	-	-	1,884	1,100
Profit before tax	14,036	17,439	(1,429)	1,191	13,780	12,182	(16,373)	(6,488)	37	721	10,051	25,046
Reportable segment assets	3,202,425	3,395,285	777,358	789,135	725,719	774,443	494,262	505,507	879,849	898,520	6,079,614	6,362,890
Reportable segment liabilities	1,909,236	2,347,992	18,336	20,511	127,067	169,645	35,268	78,202	1,516,448	1,280,922	3,606,355	3,896,272

20. Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.

Note-21 : Adoption of IFRS-16: Leases

The Group has applied IFRS 16 which has become initially applicable for the Group from 1 July 2019. As a result, the group has changed its accounting policies for lease contracts. The Group has applied IFRS 16 using restrospective approach. Therefore, comparative information have been restated.

The following table summarise the impacts of adopting IFRS 16 on the Group's consolidated financial statements:

i. Consolidated statement of financial position**1 July 2018**

Figures in '000' Taka	Impact of initial application of IFRS 16		
	As previously reported	Adjustments	As restated
Right-of-use assets (for lease contracts)	-	11,784	11,784
Retained Earnings	915,940	(559)	915,381
Deferred tax liabilities	59,511	(186)	59,325
Lease liabilities	-	12,530	12,530

30 June 2019

Figures in '000' Taka	Impact of initial application of IFRS 16		
	As previously reported	Adjustments	As restated
Right-of-use assets (for lease contracts)	-	21,371	21,371
Retained Earnings	886,894	(1,498)	885,396
Deferred tax liabilities	49,417	(499)	48,918
Lease Liabilities	-	23,368	23,368

ii. Consolidated statement of profit or loss**For the Quarter ended from July 2018 to September 2018**

Figures in '000' Taka	Impact of initial application of IFRS 16		
	As previously reported	Adjustments	As restated
Administrative, selling and distribution expenses	(205,490)	26	(205,464)
Net finance costs	(47,794)	(501)	(48,295)
Income tax expense	(7,582)	119	(7,463)
Profit for the period	17,939	(356)	17,583

iii. Consolidated statement of cash flows**For the Quarter ended from July 2018 to September 2018**

Figures in '000' Taka	Impact of initial application of IFRS 16		
	As previously reported	Adjustments	As restated
Net cash from / (used in) operating activities	(189,758)	1,138	(188,620)
Net cash from financing activities	164,611	(1,138)	163,473